Basiliximab, sold under the brand name Simulect, is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human...
9 KB (587 words) - 20:04, 20 December 2023
Barstatin 100 barucainide (INN) barusiban (INN) Basaljel basifungin (INN) basiliximab (INN) batabulin (USAN) batanopride (INN) batebulast (INN) batelapine...
5 KB (295 words) - 02:26, 1 July 2024
ankylosing spondylitis by their ability to bind to and inhibit TNF-α. Basiliximab and daclizumab inhibit IL-2 on activated T cells and thereby help prevent...
49 KB (4,964 words) - 09:59, 20 September 2024
antibodies, are also used in these conditions and include rituximab, basiliximab and eculizumab. Blood products including intravenous immunoglobulin and...
25 KB (2,838 words) - 05:46, 13 August 2024
antagonists, tyrosine kinase inhibitors, beta-glycan peptides, halofuginone, basiliximab, alemtuzumab, abatacept, and haematopoietic stem cell transplantation...
38 KB (3,293 words) - 18:29, 29 August 2024
presentation of two chimeric mouse/human anti-Tac antibodies in the year 1998: basiliximab (Simulect) and daclizumab (Zenapax). These drugs act by binding the IL-2a...
29 KB (3,378 words) - 02:54, 25 September 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
22 KB (1,789 words) - 04:29, 16 July 2024
chimeric antibodies approved for human therapy include abciximab (ReoPro), basiliximab (Simulect), cetuximab (Erbitux), infliximab (Remicade) and rituximab...
14 KB (1,787 words) - 23:05, 9 January 2024
47. BACLOFEN 48. BALSALAZIDE 49. BAMBUTEROL 50. BARBITURIC ACID 51. BASILIXIMAB 52. BENAZEPRIL HYDROCHLORIDE 53. BENIDIPINE HYDROCHLORIDE 54. BENSERAZIDE...
16 KB (253 words) - 16:47, 23 February 2023
severe damage to the graft. Anti-IL-2Rα receptor antibodies such as basiliximab and daclizumab are increasingly being used in place of ATG as an induction...
8 KB (895 words) - 14:10, 23 August 2023
including steroids, mycophenolate, and IL-2 receptor inhibitors such as basiliximab. Dosages are titrated to target blood levels at specific times after...
43 KB (4,357 words) - 08:11, 15 July 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
34 KB (2,690 words) - 02:57, 26 September 2024
use only.) Antibody drugs: Monoclonal anti-IL-2Rα receptor antibodies Basiliximab Daclizumab Monoclonal anti-IL-6R receptor antibodies Tocilizumab Polyclonal...
29 KB (3,272 words) - 23:54, 28 May 2024
Telimomab aritox Vepalimomab Zolimomab aritox Chimeric Andecaliximab† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab...
38 KB (4,316 words) - 10:24, 26 August 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
17 KB (1,245 words) - 14:04, 2 September 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
24 KB (2,070 words) - 07:13, 15 March 2024
etesevimab COVID-19 Bapineuzumab mab humanized β-amyloid Alzheimer's disease Basiliximab Simulect mab chimeric CD25 (α chain of IL-2 receptor) Y prevention of...
136 KB (4,020 words) - 06:13, 27 September 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
22 KB (2,581 words) - 20:03, 21 June 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
12 KB (1,289 words) - 19:20, 4 December 2023
form of sertraline. Signifor (pasireotide) Cushing's disease Simulect (basiliximab) Prevention of transplant rejection Sirdalud (tizanidine) Spasticity...
144 KB (12,145 words) - 21:14, 28 September 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
14 KB (1,037 words) - 22:20, 19 September 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
63 KB (7,473 words) - 11:32, 1 September 2024
Certolizumab pegol Golimumab Infliximab Nerelimomab Interleukin Anakinra Basiliximab Bimekizumab Briakinumab Brodalumab Canakinumab Daclizumab Guselkumab...
7 KB (299 words) - 13:45, 27 April 2024
pegol L04AB06 Golimumab L04AB07 Opinercept L04AC01 Daclizumab L04AC02 Basiliximab L04AC03 Anakinra L04AC04 Rilonacept L04AC05 Ustekinumab L04AC07 Tocilizumab...
3 KB (367 words) - 15:37, 25 January 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
14 KB (1,578 words) - 14:00, 26 February 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
26 KB (3,273 words) - 13:58, 26 August 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
43 KB (3,661 words) - 19:54, 27 August 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
12 KB (1,323 words) - 14:55, 7 September 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
45 KB (4,194 words) - 12:36, 2 May 2024
Interleukin 2 Pegaldesleukin Teceleukin Tucotuzumab celmoleukin Antibodies: Basiliximab Daclizumab (dacliximab) Inolimomab IL-3 Agonists: Daniplestim Interleukin...
19 KB (2,293 words) - 11:05, 8 March 2024